Selectively targeting T- and B-cell lymphomas: A benzothiazole antagonist of α 4β 1integrin

Richard D. Carpenter, Mirela Andrei, Olulanu H. Aina, Edmond Y Lau, Felice C Lightstone, Ruiwu Liu, Kit Lam, Mark J. Kurth

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Current cancer chemotherapeutic agents clinically deployed today are designed to be indiscriminately cytotoxic, however, achieving selective targeting of cancer malignancies would allow for improved diagnostic and chemotherapeutic tools. Integrin α 41, a heterodimeric cell surface receptor, is believed to have a low- affinity conformation in resting normal lymphocytes and an activated high-affinity conformation in cancerous cells, specifically T- and B-cell lymphomas. This highly attractive yet poorly understood receptor has been selectively targeted with the bisaryl urea peptidomimetic antagonist i. However, concerns regarding its preliminary pharmacokinetic (PK) profile provided an impetus to change the pharmacophore from a bisaryl urea to a 2-arylaminobenzothiazole moiety, resulting in an analogue with improved physicochemical properties, solubility, and kidney:tumor ratio while maintaining potency (6;IC 50 = 53 pM). The results presented herein utilized heterocyclic and solid-phase chemistry, cell adhesion assay, and in vivo optical imaging using the cyanine dye Cy5.5 conjugate.

Original languageEnglish (US)
Pages (from-to)14-19
Number of pages6
JournalJournal of Medicinal Chemistry
Volume52
Issue number1
DOIs
StatePublished - Jan 8 2009

Fingerprint

T-Cell Lymphoma
B-Cell Lymphoma
Urea
Neoplasms
Peptidomimetics
Optical Imaging
Cell Surface Receptors
Cell Adhesion
Integrins
Solubility
Pharmacokinetics
Lymphocytes
Kidney
benzothiazole

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery

Cite this

Selectively targeting T- and B-cell lymphomas : A benzothiazole antagonist of α 4β 1integrin. / Carpenter, Richard D.; Andrei, Mirela; Aina, Olulanu H.; Lau, Edmond Y; Lightstone, Felice C; Liu, Ruiwu; Lam, Kit; Kurth, Mark J.

In: Journal of Medicinal Chemistry, Vol. 52, No. 1, 08.01.2009, p. 14-19.

Research output: Contribution to journalArticle

Carpenter, Richard D. ; Andrei, Mirela ; Aina, Olulanu H. ; Lau, Edmond Y ; Lightstone, Felice C ; Liu, Ruiwu ; Lam, Kit ; Kurth, Mark J. / Selectively targeting T- and B-cell lymphomas : A benzothiazole antagonist of α 4β 1integrin. In: Journal of Medicinal Chemistry. 2009 ; Vol. 52, No. 1. pp. 14-19.
@article{c2a88b94ef6c480aa57542fbebbd6749,
title = "Selectively targeting T- and B-cell lymphomas: A benzothiazole antagonist of α 4β 1integrin",
abstract = "Current cancer chemotherapeutic agents clinically deployed today are designed to be indiscriminately cytotoxic, however, achieving selective targeting of cancer malignancies would allow for improved diagnostic and chemotherapeutic tools. Integrin α 4&β 1, a heterodimeric cell surface receptor, is believed to have a low- affinity conformation in resting normal lymphocytes and an activated high-affinity conformation in cancerous cells, specifically T- and B-cell lymphomas. This highly attractive yet poorly understood receptor has been selectively targeted with the bisaryl urea peptidomimetic antagonist i. However, concerns regarding its preliminary pharmacokinetic (PK) profile provided an impetus to change the pharmacophore from a bisaryl urea to a 2-arylaminobenzothiazole moiety, resulting in an analogue with improved physicochemical properties, solubility, and kidney:tumor ratio while maintaining potency (6;IC 50 = 53 pM). The results presented herein utilized heterocyclic and solid-phase chemistry, cell adhesion assay, and in vivo optical imaging using the cyanine dye Cy5.5 conjugate.",
author = "Carpenter, {Richard D.} and Mirela Andrei and Aina, {Olulanu H.} and Lau, {Edmond Y} and Lightstone, {Felice C} and Ruiwu Liu and Kit Lam and Kurth, {Mark J.}",
year = "2009",
month = "1",
day = "8",
doi = "10.1021/jm800313f",
language = "English (US)",
volume = "52",
pages = "14--19",
journal = "Journal of Medicinal Chemistry",
issn = "0022-2623",
publisher = "American Chemical Society",
number = "1",

}

TY - JOUR

T1 - Selectively targeting T- and B-cell lymphomas

T2 - A benzothiazole antagonist of α 4β 1integrin

AU - Carpenter, Richard D.

AU - Andrei, Mirela

AU - Aina, Olulanu H.

AU - Lau, Edmond Y

AU - Lightstone, Felice C

AU - Liu, Ruiwu

AU - Lam, Kit

AU - Kurth, Mark J.

PY - 2009/1/8

Y1 - 2009/1/8

N2 - Current cancer chemotherapeutic agents clinically deployed today are designed to be indiscriminately cytotoxic, however, achieving selective targeting of cancer malignancies would allow for improved diagnostic and chemotherapeutic tools. Integrin α 4&β 1, a heterodimeric cell surface receptor, is believed to have a low- affinity conformation in resting normal lymphocytes and an activated high-affinity conformation in cancerous cells, specifically T- and B-cell lymphomas. This highly attractive yet poorly understood receptor has been selectively targeted with the bisaryl urea peptidomimetic antagonist i. However, concerns regarding its preliminary pharmacokinetic (PK) profile provided an impetus to change the pharmacophore from a bisaryl urea to a 2-arylaminobenzothiazole moiety, resulting in an analogue with improved physicochemical properties, solubility, and kidney:tumor ratio while maintaining potency (6;IC 50 = 53 pM). The results presented herein utilized heterocyclic and solid-phase chemistry, cell adhesion assay, and in vivo optical imaging using the cyanine dye Cy5.5 conjugate.

AB - Current cancer chemotherapeutic agents clinically deployed today are designed to be indiscriminately cytotoxic, however, achieving selective targeting of cancer malignancies would allow for improved diagnostic and chemotherapeutic tools. Integrin α 4&β 1, a heterodimeric cell surface receptor, is believed to have a low- affinity conformation in resting normal lymphocytes and an activated high-affinity conformation in cancerous cells, specifically T- and B-cell lymphomas. This highly attractive yet poorly understood receptor has been selectively targeted with the bisaryl urea peptidomimetic antagonist i. However, concerns regarding its preliminary pharmacokinetic (PK) profile provided an impetus to change the pharmacophore from a bisaryl urea to a 2-arylaminobenzothiazole moiety, resulting in an analogue with improved physicochemical properties, solubility, and kidney:tumor ratio while maintaining potency (6;IC 50 = 53 pM). The results presented herein utilized heterocyclic and solid-phase chemistry, cell adhesion assay, and in vivo optical imaging using the cyanine dye Cy5.5 conjugate.

UR - http://www.scopus.com/inward/record.url?scp=59449093689&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=59449093689&partnerID=8YFLogxK

U2 - 10.1021/jm800313f

DO - 10.1021/jm800313f

M3 - Article

C2 - 19072684

AN - SCOPUS:59449093689

VL - 52

SP - 14

EP - 19

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

SN - 0022-2623

IS - 1

ER -